Following the value decrease of the Lifecare (LIFE-ME) share at Oslo Stock Exchange/Merkur Market Monday 12 October 2020 the company has received questions from shareholders and wants to clarify:
There are no changes in relation to Lifecare’s patented core sensor technology, Sencell, either alone or in relation to our partners Digital Diagnostics AG or the project FORGETDIABETES.
On the 3rd of October 2020, Lifecare announced that FORGETDIABETES received EUR 3.9 million, just over NOK 43 million, from a FET-Proactive announcement for development of a bionic invisible pancreas under the EU funding programme for research and innovation, Horizon 2020. The funds are partitioned on the seven parties in Italy, Germany and France, where Lifecare received EUR 570,000, close to NOK 6.3 million.
On the 25th of August 2020, Lifecare announced that Digital Diagnostics had received approval for clinical tests related to the Cantisense rapid test for Covid-19, from the Federal Institute for Drugs and Medical Devices (BfArM) in Germany. Digital Diagnostics have informed Lifecare that the clinical trials originally expected to be finalized in October 2020, are delayed due to delays in the set-up of the device production. The clinical trials are expected to take place early 2021.
Lifecare (LIFE-ME) is a Bergen-based technology company developing a miniature sensor for correct and continuous monitoring of diabetics’ blood sugar. Its patented technology is also used as a central component in a rapid test for Covid-19 and as a measurement unit for reading out different biomarkers.
For more information, please contact:
+47 40 05 90 40
Access the news on Oslo Bors NewsWeb site
515290_Lifecare – stock market announcment – clearification 13.10.20